Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Trial Details

NCT ID

NCT05789043

Phase

PHASE3

Sponsor

Peking University Cancer Hospital & Institute

Status

RECRUITING

Cancer Type

Melanoma

Interventions

• camrelizumab+apatinib+TMZ
• camrelizumab+apatinib
• camrelizumab

Locations (sample)

• Beijing, China|39.9075,116.39723

Key Eligibility Criteria

• age:≥18 years, male or female.
• Histopathologically confirmed recurrence, inoperable resection or metastatic acral melanoma (stage III/IV).
• Has not received any systematic anti-tumor drug treatment.
• Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.